China
Africa
Explore chapters and articles related to this topic
Diamond–Blackfan Anemia
Published in Dongyou Liu, Handbook of Tumor Syndromes, 2020
Anemia is observed in 90% of patients during the first year of life (median age of onset at 2 months and median age of diagnosis at 3 months) and typically manifests as a profound isolated normochromic and usually macrocytic anemia with normal leukocytes and platelets (as indicated by isolated pallor without organomegaly and dyspnea), leading to nonimmune hydrops fetalis. In some patients, hematologic disease may be mild (mild anemia, no anemia with only subtle erythroid abnormalities, physical malformations without anemia) [19].
Benign tumors and tumor-like conditions, including metaplasia
Published in T. Yee Khong, Annie N. Y. Cheung, Wenxin Zheng, Richard Wing-Cheuk Wong, Hao Chen, Diagnostic Endometrial Pathology, 2019
T. Yee Khong, Annie N. Y. Cheung, Wenxin Zheng
Extramedullary hematopoiesis is rarely identified in the endometrium, featuring variable admixture of hematopoietic cells of erythroid, myeloid and megakaryocytic lineages.85–87 Some of the reported cases were associated with underlying hematologic diseases (such as myeloproliferative disorders),85 but other cases had unknown etiology.86,87 Their recognition should trigger clinical investigations for any hematologic conditions.87
Integrative hyperthermia treatments for different types of cancer
Published in Clifford L. K. Pang, Kaiman Lee, Hyperthermia in Oncology, 2015
Clifford L. K. Pang, Kaiman Lee
Blood disease is a primary disease of the hematopoietic system, or a disease that affects the hematopoietic system, accompanied by blood abnormalities and characterized by anemia, bleeding, and fever. The hematopoietic system includes blood, bone marrow mononuclear phagocyte system, and lymphoid tissue. All that involves hematopoietic system pathology and physiology and its main manifestations of the disease belongs to the scope of hematologic diseases. Blood disease is clinically divided into three types: RBC disease, WBC disease, and bleeding and thrombotic disease. Common clinical diseases are leukemia, aplastic anemia, myelodysplastic syndrome, thrombocytopenia, multiple myeloma, lymphoma, bone fibrosis, hemophilia, thalassemia, and so on. Hematologic diseases mostly are refractory diseases. The incidence is insidious and symptoms are occult. Even if the patient is ill, he or she is often not aware of it. It is found mostly when the patient seeks medical treatment for other diseases or through health examination. Many hematologic diseases were considered incurable in the past due to the lack of effective therapy.
Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients
Published in Hematology, 2023
Wuqiang Lin, Xiuli Chen, Heyong Zheng, Zhenjie Cai
This study consecutively enrolled 82 de novo primary multiple myeloma patients from January 2018 to December 2021. Enrollment criteria contained: (i) diagnosis of de novo multiple myeloma per the International Myeloma Working Group criteria [19]; (ii) older than 18 years; (iii) received bortezomib-based induction treatment; (iv) had a willingness to participation; (v) voluntary for providing bone marrow specimen and follow-up. Exclusion criteria contained: (i) secondary or relapsed multiple myeloma; (ii) had other plasma-cell diseases or immunoglobulin-related diseases; (iii) had other malignancies; (iv) female during pregnancy or breastfeeding. Besides, 20 patients with non-malignant hematologic diseases that received bone marrow examinations were recruited as disease controls, as well as 20 healthy subjects that had bone marrow donations were recruited as healthy controls. This study had approval from Institutional Review Board. Subjects or their guardians signed the informed consent.
The disease burden of mucormycosis in Japan: results from a systematic literature review and retrospective database study
Published in Current Medical Research and Opinion, 2021
Rie Ueno, Shinichi Nishimura, Go Fujimoto, Dilinuer Ainiwaer
Our database analysis findings are largely consistent with those of a recent analysis of patients hospitalized for mucormycosis in Germany8. In that study, mortality during the index hospitalization was 41.3%, compared with 35.7% in the main group of our database analysis8. Both studies identified hematologic malignancies as the most common risk factor or baseline comorbidity (91.3% of patients described by Heimann et al. had hematologic disease, including 45.7% with acute myeloid leukemia and 13.0% with acute lymphatic leukemia)8. Similarly, both studies identified antifungal drug costs as the primary cost-driver in mucormycosis management. Heimann et al. reported a mean overall direct treatment cost of €53,261 for patients hospitalized with invasive mucormycosis, with mean antifungal treatment costs of €22,819 per patient8.
A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease
Published in Amyloid, 2020
Anne F. Brunger, Hans L. A. Nienhuis, Johan Bijzet, Wilfried W. H. Roeloffzen, Edo Vellenga, Bouke P. C. Hazenberg
In the landmark analysis at 3 months, hematologic response was assessed in 43 patients (57%). In 37 patients (49%) hematologic response was not assessed because of early death (within 3 months). Four patients (5%) were not assessed because of clinical deterioration. Patients with hematologic response (complete remission (CR); very good partial response (VGPR); partial response (PR)) (n = 27) had an overall survival median of 49 months. CR was reached in 8 patients (11%), VGPR in 10 (13%), and PR in 9 (12%) (Table 4). In patients without hematologic response (stable disease or progression) (N = 16) median overall survival was 55 months (p = .958) (Figure 1(D)). Organ response was seen in 8 patients (11%) and organ progression in 12 patients (16%). All 8 patients with organ response had a hematologic response: CR in 3 patients, VGPR in 3 patients and PR in 2 patients. Of the 12 patients with organ progression, 4 patients also had hematologic progression and 4 patients had stable hematologic disease. The remaining 4 patients had a hematologic response: PR in 2 patients, VGPR in 1 patient and CR in 1 patient.